30 results about "B16 melanoma" patented technology

The invention discloses a pharmaceutical composition and an application thereof in preparing a medicine for treating multidrug resistance of tumors and belongs to the field of biomedicines. The pharmaceutical composition is prepared from chlorogenic acid and tonka-bean quinic acid and can be used for preparing a reversal agent and a PD-1 / PD-L1 inhibitor for the multidrug resistance of the tumors.The pharmaceutical composition and the application disclosed by the invention have the beneficial effects that by combined use of the chlorogenic acid and the tonka-bean quinic acid, the synergistic interaction can be exerted, the drug-resistance reversal action on the tumor cell strain generating multidrug resistance for chemotherapeutic drugs and immunotherapeutic drugs is good, the expression of PD-1 / PD-L1 of tissues of transplanted tumors of mice with drug-resistant B16 melanoma and drug-resistant Lewis lung cancer can be effectively suppressed, and a role in proliferating CD4+T and CD8+Tcells of the mice with the drug-resistant B16 melanoma and the drug-resistant Lewis lung cancer can be effectively played.

The present invention relates to an isoxazole derivative, the compound of formula (I)herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027. Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells. Moreover, GIT27-NO induced the production of reactive oxygen species which can be neutralized by antioxidant N-acetyl cysteine (NAC), indicating that reactive oxygen species (ROS) are at least partly involved in the reduction of cell viability. The anti-tumor activity of GIT27-NO is mediated through activation of MAP kinases (ERK1 / 2, p38 and JNK) in cell-specific manner. The role of MAP kinases was further confirmed by specific inhibitors of these molecules, PD98059, SB202190, and SP600125. Finally, in vivo treatment with GIT27-NO significantly reduced tumor growth in syngeneic C57BL / 6 mice implanted with B16 melanoma.

The present invention provides cosmetic compositions for topical application to the skin. The cosmetic composition comprises a vitamin B3 compound, a ricinoleate compound and a dermatologically acceptable carrier. The vitamin B3 compound and the ricinoleate compound favorably or even synergistically up-regulate proteasomal protease activity, as evidenced by the higher than calculated net luminescence values ​​observed in B16 melanoma cells.

Here we show that SEG / SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG / SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p<0.001). In vaccination studies, DQ8 tg mice showed a surge in IFNγ serum levels reaching 3000 fold above baseline devoid of a parallel spike in TNFα levels above baseline levels. Presentation of the SEG / SEI superantigen from a MHC-DQ8 platform, therefore, augments the therapeutic index of these SAgs inducing a tumoricidal response against Lewis lung carcinoma and B16 melanoma accompanied by a sharp increase of therapeutic IFNγ levels absent toxic levels of TNFα.

The invention relates to the technical field of health-care food, in particular to a composition with whitening and acne-removing effects as well as a preparation method and application of the composition. According to the composition, medicinal and edible raw materials such as radix puerariae, radix platycodi, liquorice root, radix angelicae dahuricae and fructus momordicae are compounded according to specific proportions; the experiment shows that the composition provided by the invention has a significant inhibitory effect on melanin synthesis of B16 melanoma cells and activity of tyrosinase, can remarkably improve the ultraviolet-induced skin pigmentation of mice and has an obvious inhibitory effect on acne pathogenic bacteria such as propionibacterium, staphylococcus epidermidis and staphylococcus aureus; in addition, the composition has an obvious curative effect on rabbit ear acne. The results show that the composition disclosed by the invention has remarkable whitening and acne-removing effects.

The invention belongs to the technical fields of medicaments and foods and relates to an artocarpus hypargyreus hance extract and a preparation method and application thereof. In the artocarpus hypargyreus hance extract, the content of an isopentenyl-substituted flavonoid compound is 20 to 40 weight percent. The preparation method comprises the following steps; extracting stems and branches of artocarpus hypargyreus hance serving as a raw material by a solvent to prepare a total extract; dissolving the total extract in water, extracting with a halogenated solvent and an ester solvent in sequence; and taking an extraction phase of the ester solvent, and drying after reclaiming the solvent to obtain the artocarpus hypargyreus hance extract. Through activity tests such as tyrosinase in vitro, B16 melanoma cells, DPPH clearing and the like, results show that the artocarpus hypargyreus hance extract has strong effects of inhibiting the generation of the tyrosinase and melanin and clearing free radicals, can be used as a melanin inhibitor, a whitening agent or a natural antioxidant, and is applied to the fields of medicament, daily chemical engineering and food.

The application of pumpkin protein in pharmacy can isolate a ribosome inactivating protein-pumpkin protein from pumpkin pulp, and the protein shows good antitumor activity and can be used to prepare antitumor drugs. Pumpkin protein can significantly inhibit gastric cancer cells SGC7901 cultured in vitro, liver cancer cells HepG2, Bel7404, non-small cell lung cancer cells A549, breast cancer cells MCF-7 and melanoma cells B16, while inhibiting human normal liver cells and peripheral blood lymphocytes. The effect is small, showing obvious selectivity; pumpkin protein can also significantly inhibit cervical cancer U14, melanoma B16 and lung cancer Lewis and other animal transplanted tumors in mice. In addition, the present invention also confirms that the apoptosis-inducing and differentiation-inducing effect of pumpkin protein on tumor cells is an important mechanism of its anti-tumor activity.

The invention discloses a PTD-SOD-MUTANT protein, which is a fusion protein composed of a protein transduction domain PTD and SOD derived from thermophilic bacteria HB27, wherein the SOD amino acid sequence has double mutations of I28L and D108A. PTD‑SOD‑MUTANT protein has the advantages of good thermal stability, high activity, and can enter cells through cell membranes. In vitro and in vivo experiments show that this protein has a strong inhibitory effect on the proliferation of mouse B16 melanoma cells and mouse malignant melanoma. The combination of this protein and doxorubicin (DOX) has a synergistic effect on tumor cells. PTD‑SOD‑MUTANT proteins can be used as pharmaceutical compositions, cosmetic active components, food additives, etc., and have great application value and broad application prospects in the field of drug research and development, daily necessities, and food.

The invention discloses application of A-nor-5 alpha-androstane compounds in preparation of malignant tumor resistant medicaments. The compounds have the following general formula I, and comprise Ia, Ib, Ic, Id, Ie and If. The growth inhibition rate of the A-nor-5 alpha-androstane compounds for in-vitro human liver cancer cell Hep 3B, human breast cancer MDA-MB-231, human lung adenocarcinoma A549and mouse melanoma B16 is higher than 85% on average, and even up to 99.98% to the maximum. The in-vivo test proves that the inhibition rate of the A-nor-5 alpha-androstane compounds for mouse tumors, such as intestinal cancer C26, liver cancer H22, Lewis lung cancer, breast cancer, B16 melanoma and the like, is higher than 50% on average, and even up to 63.19% to the maximum. The result proves that the compounds disclosed by the invention have an obvious malignant tumor resistant action. The A-nor-5 alpha-androstane compounds disclosed by the invention have an obvious and broad-spectrum action on inhibiting growth of malignant tumor cells, and are novel targeted malignant tumor resistant medicaments with low drug toxicity and favorable treatment effect; and the A-nor-5 alpha-androstane compounds just specifically act on tumor cells, but not influence normal cells, thereby having a high clinical application value.